Intratumoral recombinant human interferon alpha-2a and vincristine combination therapy in canine transmissible venereal tumour

KANCA H., Tez G., Bal K., ÖZEN D., Alcigir E., VURAL S.

VETERINARY MEDICINE AND SCIENCE, cilt.4, sa.4, ss.364-372, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 4 Sayı: 4
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1002/vms3.119
  • Dergi Adı: VETERINARY MEDICINE AND SCIENCE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.364-372
  • Anahtar Kelimeler: Canine, immunochemotherapy, recombinant human interferon alpha-2a, transmissible venereal tumour, vincristine, SPONTANEOUS REGRESSION, CANCER-THERAPY, DOGS, CHEMOTHERAPY, SARCOMA, GROWTH, INTERLEUKIN-2, LYMPHOCYTES, TGF-BETA-1, MANAGEMENT
  • Ankara Üniversitesi Adresli: Evet

Özet

Canine transmissible venereal tumour (CTVT) is a naturally occurring contagious neoplasm of dogs located mainly on the external genitalia of both sexes. The course of vincristine chemotherapy, the most effective and practical therapy, is affected by the immune status of the host. The aim was to investigate recombinant human interferon alpha-2a (rhIFN alpha-2a) and vincristine for treatment of CTVT. A total of 21 female dogs were included. In group I (n = 9), vincristine (0.025 mg/kg, IV) was administered weekly. In group II (n = 6), dogs were injected intratumorally weekly with 1.5 million IU rhIFN alpha-2a. In group III (n = 6), rhIFN alpha-2a and vincristine were combined. No tumour regression was observed after three injections of rhIFN alpha-2a in group II and weekly vincristine was administered. The number of tumour infiltrating lymphocytes (TILs), mitotic figures and apoptotic cells were counted in subsequent incisional tumour biopsies. The Kaplan-Meier Method was used to analyse survival using complete tumour regression as the outcome and Breslow Test was used for comparison of survival curves. Differences in TILs, cell proliferation and apoptosis between groups were assessed by analysis of covariance. Complete regression was observed in all animals included. Mean duration of vincristine treatment for complete regression was shorter in group II (3.50 weeks, 95% CI, 3.06-3.94, P < 0.05) and group III (3.17 weeks, 95% CI, 2.84-3.49, P < 0.01) compared to group I (5.11 weeks, 95% CI, 4.42-5.80). Vincristine and rhIFN alpha-2a combination increased TILs in CTVT biopsies compared to vincristine treatment (P = 0.017) and vincristine treatment after rhIFN alpha-2a (P = 0.049). Vincristine treatment after rhIFN alpha-2a (Group II; P < 0.001) and rhIFN alpha-2a and vincristine combination (Group III; P < 0.001) decreased apoptosis. The results indicate that intratumoral rhIFN alpha-2a treatment alone is not effective in CTVT. However, combination of rhIFN alpha-2a and vincristine shortens the duration of treatment compared to vincristine therapy.